Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.38 |
| ▸ | GAA known ✓ | P10253 | 5/20 | 0.37 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8024 | 0.98 | — | — | |
| SCHEMBL25275928 | 0.96 | GDA (0.50) | GDAPARP1HSD17B10CYP2C19GAA | |
| Phosphoric Acid SCHEMBL7627085 | 0.90 | GDA (0.46) | GDAPARP1HSD17B10CYP2C19GAA | |
| SCHEMBL3258892 | 0.82 | GDA (0.43) | GDAHSD17B10CYP2C19GAAALDH1A1 | |
| SCHEMBL71570 | 0.80 | — | — | |
| SCHEMBL13176680 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL10712747 | 0.78 | GDA (0.45) | GDAPARP1HSD17B10CYP2C19GAA | |
| SCHEMBL19018643 | 0.78 | GAA (0.51) | GDAHSD17B10CYP2C19GAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL17984761 | 0.78 | GDA (0.41) | GDAGAALMNAKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL3986298 | 0.78 | GDA (0.61) | GDAPARP1HSD17B10CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031289-A1 | POLY(ORGANOPHOSPHAZENE) CONTAINING DEGRADATION CONTROLLABLE IONIC GROUP, PREPARATION METHOD THEREOF AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-01-30 | — | — | US | claimed |
| US-20070225496-A1 | PROCESS FOR PREPARING TEMOZOLOMIDE | DR. REDDY'S LABORATORIES, INC. | 2007-09-27 | — | — | US | claimed |
| EP-0840608-A4 | TREATMENT AND PREVENTION OF NEOPLASMS WITH SALTS OF AMINOIMIDAZOLE CARBOXAMIDE AND 5-AMINO OR SUBSTITUTED AMINO 1,2,3-TRIAZOLES | CONSTANTIA GRUPPE (AT) | 2002-10-02 | — | — | EP | claimed |
| EP-0840608-A1 | TREATMENT AND PREVENTION OF NEOPLASMS WITH SALTS OF AMINOIMIDAZOLE CARBOXAMIDE AND 5-AMINO OR SUBSTITUTED AMINO 1,2,3-TRIAZOLES | Constantia Gruppe (AT) | 1998-05-13 | — | — | EP | claimed |
| WO-1997003668-A1 | TREATMENT AND PREVENTION OF NEOPLASMS WITH SALTS OF AMINOIMIDAZOLE CARBOXAMIDE AND 5-AMINO OR SUBSTITUTED AMINO 1,2,3-TRIAZOLES | CONSTANTIA GRUPPE (AT) | 1997-02-06 | — | — | WO | claimed |
| CN-118766906-A | Stable antitumor pharmaceutical composition containing temozolomide and preparation method of composition | 双键医药品股份公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-109790164-B | Purine and 3-deazapurine analogues as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2022-01-25 | — | — | CN | disclosed |
| US-10806732-B2 | Stable anti-neoplastic pharmaceutical composition comprising temozolomide and method of preparing the composition | Double Bond Pharmaceutical AB (SE) | 2020-10-20 | — | — | US | disclosed |
| US-10683292-B2 | Purine and 3-deazapurine analogues as choline kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-06-16 | — | — | US | disclosed |
| EP-3452017-B1 | STABLE ANTI-NEOPLASTIC PHARMACEUTICAL COMPOSITION COMPRISING TEMOZOLOMIDE AND METHOD OF PREPARING THE COMPOSITION | Double Bond Pharmaceutical AB (SE) | 2020-02-19 | — | — | EP | disclosed |
| US-20190225615-A1 | PURINE AND 3-DEAZAPURINE ANALOGUES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-07-25 | — | — | US | disclosed |
| EP-3487857-A1 | PURINE AND 3-DEAZAPURINE ANALOGUES AS CHOLINE KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2019-05-29 | — | — | EP | disclosed |
| US-20020133006-A1 | Synthesis of temozolomide and analogs | SCHERING CORPORATION | 2002-09-19 | — | — | US | disclosed |
| WO-2002057269-A1 | SYNTHESIS OF TEMOZOLOMIDE AND ANALOGS | SCHERING CORPORATION (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020095036-A1 | Synthesis of temozolomide and analogs | SCHERING CORPORATION | 2002-07-18 | — | — | US | disclosed |
| US-5077288-A | Adrenergic, serotonin and histamine antagonist | ADIR ET COMPAGNIE (FR) | 1991-12-31 | — | — | US | disclosed |
| US-4668580-A | CARBONLESS COPYING PAPER | BAYER AKTIENGESELLSCHAFT (DE) | 1987-05-26 | — | — | US | disclosed |
| US-4659720-A | POULTRY ANTIPROTOZOA AGENT | MERCK & CO., INC. (US) | 1987-04-21 | — | — | US | disclosed |
| EP-0113570-B1 | 5-(AMINO OR SUBSTITUTED AMINO) IMIDAZOLES | MERCK & CO. INC. (US) | 1987-02-25 | — | — | EP | disclosed |
| EP-0113570-A1 | 5-(Amino or substituted amino) imidazoles | MERCK & CO. INC. (US) | 1984-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225496-A1 | PROCESS FOR PREPARING TEMOZOLOMIDE | MGMT, TET2, FIP1L1 | PARP1 9/4885GAA 2801/4885GDA 1108/4885 |
| US-10806732-B2 | Stable anti-neoplastic pharmaceutical composition comprising temozolomide and method of preparing the composition | MGMT, MYD88, WASHC5 | PARP1 1784/4885GAA 3847/4885GDA 906/4885 |
| US-20140031289-A1 | POLY(ORGANOPHOSPHAZENE) CONTAINING DEGRADATION CONTROLLABLE IONIC GROUP, PREPARATION METHOD THEREOF AND USE THEREOF | PHOSPHO1, PLCB3, INPP5D | PARP1 3083/4885GAA 1306/4885GDA 728/4885 |
| US-10683292-B2 | Purine and 3-deazapurine analogues as choline kinase inhibitors | DCK, CHKA, ADK | PARP1 198/4885GAA 834/4885GDA 104/4885 |
| US-20020133006-A1 | Synthesis of temozolomide and analogs | MGMT, TYMS, MCL1 | PARP1 54/4885GAA 3337/4885GDA 127/4885 |
| US-20190225615-A1 | PURINE AND 3-DEAZAPURINE ANALOGUES AS CHOLINE KINASE INHIBITORS | DCK, CHKA, ADK | PARP1 198/4885GAA 834/4885GDA 104/4885 |
| US-20020095036-A1 | Synthesis of temozolomide and analogs | MGMT, TYMS, MCL1 | PARP1 45/4885GAA 3301/4885GDA 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.